Şahin Bodur

Şahin Bodur

Auto-generated profile, based on publicly available information

Şahin Bodur

Department of Child and Adolescent Psychiatry, University of Health Sciences, Gulhane Training and Research Hospital, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2015 in Journal of Autism and Developmental Disorders
Verified
Journal Article
Closed access
PDF file
EKEmrah Utku Kabataş
Emrah Utku Kabataş
POPinar Altiaylik Ozer
Pinar Altiaylik Ozer
GEGokce Tasdemir Ertugrul
Gokce Tasdemir Ertugrul
BKBengi Ece Kurtul
Bengi Ece Kurtul
SBSahin Bodur
Sahin Bodur
BABurcu Ersoz Alan
Burcu Ersoz Alan

1 August 2019 in Archives of Clinical Psychiatry (São Paulo)
Verified
Journal Article
Open access
PDF file
SBSahin Bodur
Sahin Bodur
YTYasemin Tas Torun
Yasemin Tas Torun
HGHesna Gül
Hesna Gül
MDMustafa Dinçer
Mustafa Dinçer
AGAhmet Gül
Ahmet Gül
MCMehmet Ayhan Cöngöloglu
Mehmet Ayhan Cöngöloglu
Key words: Parental attitudes; persistent developmental stuttering; severity

26 October 2022 in Clinical Neuropharmacology
Verified
Journal Article
Closed access
OGOya Güleşen
Oya Güleşen
ŞBŞahin Bodur
Şahin Bodur
ACAyhan Cöngöloğlu
Ayhan Cöngöloğlu
Objectives: Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders of childhood. Although enuresis is a very common disorder in child diagnosed with ADHD, it may also develop because of methylphenidate. Methods: Authors report here on a child case of ADHD that developed a probable enuresis related to methylphenidate. Results and Conclusions: Clinicians should be aware that methylphenidate used in ADHD causes dose-dependent enuresis.

1 September 2016 in Klinik Psikofarmakoloji Bülteni / Bulletin of Clinical Psychopharmacology
Verified
Journal Article
Open access
SBSahin Bodur
Sahin Bodur
CTCandan Taskiran
Candan Taskiran
YIYetis Isildar
Yetis Isildar
BABurcu Alan
Burcu Alan
MCMiray Cetinkaya
Miray Cetinkaya
STSevil Turgut
Sevil Turgut

1 January 2014 in American Journal of Psychiatry and Neuroscience
Verified
Journal Article
Open access
PDF file
SBSahin Bodur
Sahin Bodur
YIYetis Isildar
Yetis Isildar
HKHalil Kara
Halil Kara
MSMurat Sabanci
Murat Sabanci
Attention-Deficit/Hyperactivity Disorder (ADHD) is the most common neurodevelopmental disorder in children that shows comorbidity with several psychopathology included stuttering. The prefrontal cortex is the area of brain that sends and receives projections from virtually all cortical sensory systems, motor systems, and many subcortical structures. It has been shown that psychostimulant medication increases activation of the inferior prefrontal cortex and the basal ganglia. Both functional neuroimaging and neuropsychological studies show that psychostimulant medication improves executive functions. Verbal fluency is also considered as one of the executive functions. In this article, we report osmotic-controlled release oral delivery system (OROS) methylphenidate treatment effectiveness of stuttering that combined with ADHD.

30 December 2021 in Düzce Tıp Fakültesi Dergisi
Verified
Journal Article
Open access
PDF file
AEAyşe Nihal ERASLAN
Ayşe Nihal ERASLAN
IDİbRahim Durukan
İbRahim Durukan
ŞBŞahin Bodur
Şahin Bodur
ÖDÖzge Demi̇rCan
Özge Demi̇rCan
Aim: Autism spectrum disorder is a neurodevelopmental disorder. The S100 calcium binding protein B (S100B) is among the markers of astrocyte activation as well as brain damage. Herein, it was aimed to evaluate S100B levels to determine whether there is a relation with the severity of autism spectrum disorder and establish possible causes of different results among the studies in the literature from a psychiatric and biochemical perspective. Material and Methods: Twenty-five male children with autism spectrum disorder were included as the study group along with twenty-seven male children as the control group. The childhood autism rating scale and the autism behavior checklist were applied. Serum S100B protein levels were measured by enzyme-linked immunosorbent assay (ELISA). Results: The mean serum S100B level was 1008.61±171.34 pg/mL in the study group and 1060.14±182.83 pg/mL in the control group, and no statistically significant difference was found between the groups (p=0.300). Based on the childhood autism rating scale scores, 60% (n=15) of the children with autism spectrum disorder had severe autism, whereas 40% (n=10) had mild-to-moderate autism. There was no significant difference in terms of the serum S100B levels between the groups of autism spectrum disorder severity (p=0.935) or according to the autistic regression status (p=0.667). Conclusion: For S100B to be accepted as a reliable biomarker for autism spectrum disorder, more studies considering some factors with larger samples should be performed. Moreover, to understand the effect of biochemical methodology on the results, further studies are suggested on this subject.